Rubius Therapeutics Inc

Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

We have developed our proprietary RED PLATFORM® to generate red blood cells and biologically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of biological engineering to deliver on the promise of cellular therapy and transform how diseases are treated.